Status:
COMPLETED
Clinical Study Of Schizophrenia in Both Men and Women
Lead Sponsor:
GlaxoSmithKline
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophr...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception.
- Diagnosis of Schizophrenia
- Patients must be taking clozapine monotherapy or other atypical antipsychotic at least 3 months prior to this study.
- Exclusion criteria:
- Patients who are currently taking or have taken antidepressant medication in the last month prior.
- Patients who are or have been suicidal or homicidal in the last 6 months.
- Patients with a history of autistic disorder or another pervasive developmental disorder
- Patients whose condition is due to the direct physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medical condition
Exclusion
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
End Date :
January 1 2005
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT00071747
Start Date
August 1 2003
End Date
January 1 2005
Last Update
September 1 2016
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Little Rock, Arkansas, United States, 72201
2
GSK Investigational Site
Garden Grove, California, United States, 92845
3
GSK Investigational Site
La Mesa, California, United States, 91942
4
GSK Investigational Site
National City, California, United States, 91950